Seres Therapeutics Inc (MCRB) concluded trading on Thursday at a closing price of $0.74, with 10.63 million shares of worth about $7.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.34% during that period and on January 16, 2025 the price saw a loss of about -5.77%. Currently the company’s common shares owned by public are about 170.20M shares, out of which, 124.81M shares are available for trading.
Stock saw a price change of -13.53% in past 5 days and over the past one month there was a price change of -16.34%. Year-to-date (YTD), MCRB shares are showing a performance of -11.55% which decreased to -40.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Seres Therapeutics Inc shares is 2.49 million. The stock is currently trading -15.02% below its 20-day simple moving average (SMA20), while that difference is down -10.38% for SMA50 and it goes to -16.96% lower than SMA200.
Seres Therapeutics Inc (NASDAQ: MCRB) currently have 170.20M outstanding shares and institutions hold larger chunk of about 23.58% of that.
The stock has a current market capitalization of $125.50M and its 3Y-monthly beta is at 2.11. It has posted earnings per share of -$1.19 in the same period. It has Quick Ratio of 1.12 while making debt-to-equity ratio of 3.91. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MCRB, volatility over the week remained 8.69% while standing at 7.66% over the month.
Analysts are in expectations that Seres Therapeutics Inc (MCRB) stock would likely to be making an EPS of -0.21 in the current quarter, while forecast for next quarter EPS is -0.19 and it is -0.41 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.28 which is -0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.28 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 86.52% while it is estimated to decrease by -175.37% in next year.
Coverage by Oppenheimer stated Seres Therapeutics Inc (MCRB) stock as an Outperform in their note to investors on June 26, 2023, suggesting a price target of $12 for the stock. On April 21, 2023, JP Morgan Initiated their recommendations, while on July 23, 2021, Goldman Downgrade their ratings for the stock with a price target of $7. Stock get a Neutral rating from Goldman on May 18, 2021.
